119 related articles for article (PubMed ID: 33629256)
1. Constant infusion case of one compartment pharmacokinetic model with simultaneous first-order and Michaelis-Menten elimination: analytical solution and drug exposure formula.
Wu X; Chen M; Li J
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):495-508. PubMed ID: 33629256
[TBL] [Abstract][Full Text] [Related]
2. An Analytical Approach of One-Compartmental Pharmacokinetic Models with Sigmoidal Hill Elimination.
Wu X; Zhang H; Li J
Bull Math Biol; 2022 Sep; 84(10):117. PubMed ID: 36100829
[TBL] [Abstract][Full Text] [Related]
3. Analytical Solution and Exposure Analysis of a Pharmacokinetic Model with Simultaneous Elimination Pathways and Endogenous Production: The Case of Multiple Dosing Administration.
Wu X; Nekka F; Li J
Bull Math Biol; 2019 Sep; 81(9):3436-3459. PubMed ID: 31420841
[TBL] [Abstract][Full Text] [Related]
4. Mathematical analysis and drug exposure evaluation of pharmacokinetic models with endogenous production and simultaneous first-order and Michaelis-Menten elimination: the case of single dose.
Wu X; Nekka F; Li J
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):693-705. PubMed ID: 29987574
[TBL] [Abstract][Full Text] [Related]
5. Closed form solutions and dominant elimination pathways of simultaneous first-order and Michaelis-Menten kinetics.
Wu X; Li J; Nekka F
J Pharmacokinet Pharmacodyn; 2015 Apr; 42(2):151-61. PubMed ID: 25678215
[TBL] [Abstract][Full Text] [Related]
6. One-compartment model with Michaelis-Menten elimination kinetics and therapeutic window: an analytical approach.
Tang S; Xiao Y
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):807-27. PubMed ID: 17874283
[TBL] [Abstract][Full Text] [Related]
7. Steady-state volume of distribution of two-compartment models with simultaneous linear and saturated elimination.
Wu X; Nekka F; Li J
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):447-59. PubMed ID: 27405818
[TBL] [Abstract][Full Text] [Related]
8. Simulation for population analysis of Michaelis-Menten elimination kinetics.
Hashimoto Y; Koue T; Otsuki Y; Yasuhara M; Hori R; Inui K
J Pharmacokinet Biopharm; 1995 Apr; 23(2):205-16. PubMed ID: 8719237
[TBL] [Abstract][Full Text] [Related]
9. Relationships between steady-state and single-dose plasma drug concentrations for pharmacokinetic systems with nonlinear elimination.
Cheng HY; Jusko WJ
Biopharm Drug Dispos; 1989; 10(5):513-28. PubMed ID: 2804255
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
[TBL] [Abstract][Full Text] [Related]
11. Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data.
Ocampo-Pelland AS; Gastonguay MR; French JF; Riggs MM
J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):191-206. PubMed ID: 26872884
[TBL] [Abstract][Full Text] [Related]
12. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
[TBL] [Abstract][Full Text] [Related]
13. Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs.
Saganuwan SA
BMC Pharmacol Toxicol; 2021 Oct; 22(1):57. PubMed ID: 34635182
[TBL] [Abstract][Full Text] [Related]
14. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of hydroxyurea in cancer patients.
Tracewell WG; Trump DL; Vaughan WP; Smith DC; Gwilt PR
Cancer Chemother Pharmacol; 1995; 35(5):417-22. PubMed ID: 7850924
[TBL] [Abstract][Full Text] [Related]
16. Explicit reformulations of the Lambert W-omega function for calculations of the solutions to one-compartment pharmacokinetic models with Michaelis-Menten elimination kinetics.
Goličnik M
Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):121-7. PubMed ID: 21533844
[TBL] [Abstract][Full Text] [Related]
17. Non-linear pharmacokinetic modelling of intravenous elgodipine.
de la Motte S; Alberich X; Harrison F
Int J Clin Pharmacol Ther; 1999 Jan; 37(1):20-7. PubMed ID: 10027479
[TBL] [Abstract][Full Text] [Related]
18. A nonlinear physiologic pharmacokinetic model: I. Steady-state.
Wagner JG; Szpunar GJ; Ferry JJ
J Pharmacokinet Biopharm; 1985 Feb; 13(1):73-92. PubMed ID: 4020623
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.
Vinks AA; Den Hollander JG; Overbeek SE; Jelliffe RW; Mouton JW
Antimicrob Agents Chemother; 2003 Feb; 47(2):541-7. PubMed ID: 12543656
[TBL] [Abstract][Full Text] [Related]
20. Dexmedetomidine Clearance Decreases with Increasing Drug Exposure: Implications for Current Dosing Regimens and Target-controlled Infusion Models Assuming Linear Pharmacokinetics.
Alvarez-Jimenez R; Weerink MAS; Hannivoort LN; Su H; Struys MMRF; Loer SA; Colin PJ
Anesthesiology; 2022 Feb; 136(2):279-292. PubMed ID: 34851425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
